ES2128369T3 - Procedimiento para la fabricacion de formas farmaceuticas solidas con liberacion prolongada en dos etapas. - Google Patents

Procedimiento para la fabricacion de formas farmaceuticas solidas con liberacion prolongada en dos etapas.

Info

Publication number
ES2128369T3
ES2128369T3 ES93112018T ES93112018T ES2128369T3 ES 2128369 T3 ES2128369 T3 ES 2128369T3 ES 93112018 T ES93112018 T ES 93112018T ES 93112018 T ES93112018 T ES 93112018T ES 2128369 T3 ES2128369 T3 ES 2128369T3
Authority
ES
Spain
Prior art keywords
procedure
stages
manufacture
solid pharmaceutical
pharmaceutical forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93112018T
Other languages
English (en)
Inventor
Eberhard Prof Dr Nurnberg
Ehrhard Dr Seiller
Stefan Ritsert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz and Co GmbH and Co KG
Original Assignee
Merz and Co GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz and Co GmbH and Co KG filed Critical Merz and Co GmbH and Co KG
Application granted granted Critical
Publication of ES2128369T3 publication Critical patent/ES2128369T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN PROCEDIMIENTO PARA LA PRODUCCION DE FORMAS MEDICINALES SOLIDAS CON DOS ETAPAS DE DISPOSICION LIBRE RETARDADAS,QUE SE CARACTERIZA A TRAVES DE LA ADICION DE UNAS SALES DE CASEINA SOLUBLES EN AGUA ASI COMO INSOLUBLES EN AGUA , PARTICULARMENTE CASEINATO DE SODIO Y CALCIO EN UNA RELACION AMPLIA Y EN UNA CANTIDAD TOTAL DE 5-98 %.EL PROCEDIMIENTO ES APROPIADO PARA LA PRODUCCION DE MOLDES CONTENIENDO MEMANTINA COMO SUBSTANCIA ACTIVA.
ES93112018T 1992-08-04 1993-07-28 Procedimiento para la fabricacion de formas farmaceuticas solidas con liberacion prolongada en dos etapas. Expired - Lifetime ES2128369T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4225730A DE4225730C2 (de) 1992-08-04 1992-08-04 Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung

Publications (1)

Publication Number Publication Date
ES2128369T3 true ES2128369T3 (es) 1999-05-16

Family

ID=6464804

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93112018T Expired - Lifetime ES2128369T3 (es) 1992-08-04 1993-07-28 Procedimiento para la fabricacion de formas farmaceuticas solidas con liberacion prolongada en dos etapas.

Country Status (17)

Country Link
US (1) US5382601A (es)
EP (1) EP0582186B1 (es)
JP (1) JP3560244B2 (es)
CN (1) CN1086708A (es)
AT (1) ATE176866T1 (es)
AU (1) AU669731B2 (es)
CA (1) CA2141691C (es)
DE (2) DE4225730C2 (es)
DK (1) DK0582186T3 (es)
ES (1) ES2128369T3 (es)
GR (1) GR3030227T3 (es)
IL (1) IL106580A (es)
LT (1) LT3201B (es)
LV (1) LV10182B (es)
MX (1) MX9304675A (es)
WO (1) WO1994003158A1 (es)
ZA (1) ZA935614B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
AU3860797A (en) * 1997-07-16 1999-02-10 Antrin Research Limited Pharmaceutical formulations for oral administration
US5840334A (en) * 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5980941A (en) * 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
DE19809242A1 (de) * 1998-03-05 1999-09-09 Basf Ag Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix
DE19814257A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1852113A3 (en) * 2000-12-07 2008-03-12 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
EP1727538A2 (en) * 2004-02-13 2006-12-06 Neuromolecular Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
WO2005079756A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
BRPI0512263A (pt) * 2004-06-17 2008-02-26 Merz Pharma Gmbh & Co Kgaa formulações de liberação imediata de formas de dosagem oral de memantina
KR100901927B1 (ko) * 2004-06-17 2009-06-10 메르츠 파마 게엠베하 운트 코. 카가아 메만타인 또는 네라멕산의 직접 압축으로 제조된 마실수 있는 즉시 방출형 제제
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
WO2006009769A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
AU2005309601A1 (en) 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
CA2592605C (en) * 2004-12-27 2010-12-07 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
CA2604617C (en) * 2005-04-28 2014-06-17 Eisai R&D Management Co., Ltd. Composition containing anti-dementia drug
US20060286167A1 (en) * 2005-05-02 2006-12-21 Jane Staunton Compositions and methods for the treatment of neurodegenerative diseases
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
CN101361000B (zh) * 2005-12-23 2013-04-17 爱尔开-阿贝优公司 用于药用产品溶出试验的方法
EP2040676A2 (en) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Orally dissolving formulations of memantine
US7624743B2 (en) * 2006-09-14 2009-12-01 Halliburton Energy Services, Inc. Methods and compositions for thermally treating a conduit used for hydrocarbon production or transmission to help remove paraffin wax buildup
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
EP2583669A1 (en) 2007-10-10 2013-04-24 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
EP2363119A1 (fr) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires
US20140004189A1 (en) 2011-01-25 2014-01-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
WO2012110912A1 (en) 2011-02-17 2012-08-23 Lupin Limited Sustained release composition of memantine
TR201104108A2 (tr) 2011-04-27 2011-08-22 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salımlı memantin tablet.
FR2980973B1 (fr) * 2011-10-11 2013-11-15 Univ Clermont Auvergne Composition pour le traitement prophylactique de la douleur neuropathique.
US20130274342A1 (en) * 2012-04-12 2013-10-17 Cerecor, Inc. Compositions and methods for treating cough
ES2623176T3 (es) 2012-08-16 2017-07-10 Teva Pharmaceutical Industries Ltd. Composición farmacéutica de memantina
WO2014122077A1 (de) * 2013-02-08 2014-08-14 Basf Se Herstellung von anorganisch-organischen kompositmaterialien durch reaktive sprühtrocknung
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CA3072764A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US11602507B2 (en) 2019-05-27 2023-03-14 Trikona Pharmaceuticals Pvt. Ltd Extended release oral composition of memantine or its salt and its process for the preparation
CU24720B1 (es) 2020-11-24 2024-10-09 Centro De Neurociencias De Cuba Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release
EP4678167A1 (en) * 2024-07-04 2026-01-14 Laboratorio della Farmacia S.p.A. Solid oral composition with gradual enteric release for lipophilic active ingredients

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB715874A (en) * 1952-10-03 1954-09-22 Horlicks Ltd A tablet for use in treating peptic ulcers
GB840091A (en) * 1955-09-08 1960-07-06 Upjohn Co Improvements in or relating to therapeutic compositions and the manufacture thereof
US3594467A (en) * 1968-10-09 1971-07-20 Richardson Merrell Inc Long-lasting troche
NL7305644A (es) * 1972-04-20 1973-10-23
US4076846A (en) * 1974-11-22 1978-02-28 Sumitomo Bakelite Company Limited Protein-starch binary molding composition and shaped articles obtained therefor
US4127650A (en) * 1975-03-31 1978-11-28 William H. Rorer, Inc. Medicinal simethicone containing composition and its method of production
US4419369A (en) * 1980-09-22 1983-12-06 Baylor College Of Medicine Protein mineral dietary module
US4346112A (en) * 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
EP0211294A3 (en) * 1985-08-06 1988-11-17 Eltech Systems Corporation Treating agent for liquid media
US4897380A (en) * 1985-08-30 1990-01-30 Pollack Robert L Method and composition for relieving dietary-related disorders
US4853377A (en) * 1985-10-15 1989-08-01 Pollack Robert L Method and composition for increasing production of serotonin
DK179687D0 (da) * 1987-04-08 1987-04-08 Farma Food As Praeparat
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
DE10299048I2 (de) * 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
CA2071867A1 (en) * 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
GB9004950D0 (en) * 1990-03-06 1990-05-02 Kelco Int Ltd Controlled release formulation
AU7991191A (en) * 1990-05-23 1991-12-10 Southwest Research Institute Filament system for delivering a medicament and method
FR2664499B1 (fr) * 1990-07-16 1994-11-04 Jacques Dubois Nouvelles formes pharmaceutiques, leur procede de preparation et leurs applications.

Also Published As

Publication number Publication date
AU669731B2 (en) 1996-06-20
ZA935614B (en) 1995-02-03
LV10182A (lv) 1994-10-20
CA2141691C (en) 2002-04-09
AU4706993A (en) 1994-03-03
DE4225730C2 (de) 2003-04-30
DE59309388D1 (de) 1999-04-01
LTIP839A (lt) 1994-08-25
LT3201B (en) 1995-03-27
US5382601A (en) 1995-01-17
MX9304675A (es) 1994-03-31
CN1086708A (zh) 1994-05-18
DK0582186T3 (da) 1999-09-27
ATE176866T1 (de) 1999-03-15
GR3030227T3 (en) 1999-08-31
EP0582186A1 (de) 1994-02-09
IL106580A (en) 1998-02-08
EP0582186B1 (de) 1999-02-24
CA2141691A1 (en) 1994-02-17
IL106580A0 (en) 1993-12-08
LV10182B (en) 1995-04-20
WO1994003158A1 (en) 1994-02-17
JP3560244B2 (ja) 2004-09-02
DE4225730A1 (de) 1994-02-10
JPH07509479A (ja) 1995-10-19

Similar Documents

Publication Publication Date Title
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
ES2139798T3 (es) Matriz de liberacion controlada para productos farmaceuticos.
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
MX9307686A (es) Preparacion de liberacion sostenida.
ES2111547T3 (es) Comprimido de liberacion prolongada.
ES541521A0 (es) Un procedimiento para la preparacion de piridazinaminas.
MX9304675A (es) Composicion farmaceutica solida en forma de dosis, que tiene un perfil de liberacion extendido, de dos etapas y proceso para su preparacion.
KR870006896A (ko) 서방성 약제학적 제제의 제조방법
ATE22535T1 (de) Pharmazeutische zusammensetzungen fuer die kontinuierliche freigabe des wirkstoffes.
ES2176885T3 (es) Disolucion sin gel.
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
ES2065701T3 (es) Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas.
ES2038643T3 (es) Procedimiento para la obtencion de una composicion farmaceutica topica.
ES2055177T3 (es) Composicion de gemfibrozil con liberacion modificada.
ES2037385T3 (es) Un procedimiento de manufactura de una preparacion farmaceutica para administracion local.
ES2139800T3 (es) Preparaciones farmaceuticas liposomales inyectables.
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
SE9003903D0 (sv) New pharmaceutical formulations
EA200001201A2 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
ES2184131T3 (es) Derivados de benzamidina y su utilizacion como medicamentos con efecto antagonista de ltb4.
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
ES2110212T3 (es) Composicion farmaceutica efervescente que contiene ibuprofeno y su procedimiento de preparacion.
ES2192256T3 (es) Soluciones farmaceuticas inyectables que contienen paracetamol y combinaciones de paracetamol con otras sustancias activas.
ES2066062T3 (es) Preparacion de liberacion sostenida para administracion al cerebro.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 582186

Country of ref document: ES